Mettler-Toledo International (MTD) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
8 Jul, 2026Executive summary
Q2 2024 sales declined 4% year-over-year to $946.8M, with strong growth in Europe and the Americas offset by significant weakness in China and Asia/Rest of World.
Productivity and margin initiatives, including digitalization and process harmonization, helped offset foreign exchange headwinds and support earnings.
Service revenue grew 5–6% in Q2, building on double-digit growth in the prior year and offsetting product sales declines.
Net earnings for Q2 2024 were $221.8M, up 4% year-over-year, aided by a $23M one-time non-cash discrete tax benefit from a favorable tax audit settlement.
Management remains focused on gaining market share and strengthening its position despite ongoing market softness, especially in China.
Financial highlights
Q2 2024 net sales were $946.8M, down 4% year-over-year; local currency sales declined 2% due to a 2% negative currency impact.
Adjusted operating profit was $284.1M, down 8% year-over-year; adjusted operating margin at 30.0%, down 130 bps.
Adjusted EPS for Q2 was $9.65, down 5% year-over-year; reported EPS was $10.37, up from $9.69 due to the tax benefit.
Gross margin for Q2 was 59.7%, up 30 bps year-over-year.
Adjusted free cash flow for the first six months was $433.4M, up from $395.9M in the prior year.
Outlook and guidance
Q3 2024: Local currency sales expected to grow ~1%; adjusted EPS $9.90–$10.05; currency headwind ~1%.
Full year 2024: Local currency sales growth ~2%; adjusted EPS $40.20–$40.50 (raised midpoint); FX headwind of 1% to sales and 2% to EPS.
Adjusted free cash flow and share repurchases both expected at ~$850M for 2024.
Management expects sales growth to return in the second half, driven by easier comparisons and execution of sales and marketing initiatives.
2025 will face a ~1.5% sales headwind as delayed 2023 shipments are recaptured in 2024.
Latest events from Mettler-Toledo International
- Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 20259 Jul 2026 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q4 2025 delivered 8% sales and EPS growth, with a strong outlook for 2026.MTD
Q4 20258 Jul 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference8 Jul 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance tempered by headwinds.MTD
Q4 20248 Jul 2026 - Q1 sales fell 5% to $883.7M, but margin gains and lab growth offset tariff headwinds.MTD
Q1 20258 Jul 2026 - Adjusted EPS up 9% and sales up 7% in Q1 2026, with raised full-year EPS guidance.MTD
Q1 202614 May 2026 - Strong earnings, innovation, and China-led growth support a positive second-half outlook.MTD
Bank of America Global Healthcare Conference 202613 May 2026 - Annual meeting covers director elections, auditor ratification, and performance-based executive pay.MTD
Proxy Filing18 Mar 2026